📇 Rhumatologue · ANNECY · (74) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
131.5 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR CHRISTOPHE VERMEULEN
5 AVENUE DE GENEVE, 74000 ANNECY
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Contact dermatitis · 2014
SummaryBackgroundThe preservative methylisothiazolinone (MI) is used in combination with methylchloroisothiazolinone (MCI), but theMCI/MImixture has been identified as highly allergenic.MIis considered to be less allergenic, and since the mid‐2000s has been widely used alone, but is now clearly identified as a contact allergen. TheFrenchVigilanceNetwork forDermatology andAllergy of theStudy andResearchGroup onContactDermatitis (REVIDAL‐GERDA) addedMIto its baseline patch testing series in 2010.ObjectiveTo evaluate the change in the proportion ofMI‐positive tests inFrance between 2010 and 2012.Patients/materials/methodsWe conducted a nationwide, multicentre, retrospective study of allMI‐tested patients between 2010 and 2012.ResultsSixteen centres participated in the study (7874 patients were tested). Patch tests were performed mainly at a concentration ofMI200 ppm aq. We observed a significant increase in the proportion ofMI‐positive tests in 2012 and 2011 as compared with 2010 (5.6%, 3.3%, and 1.5%, respectively;p < 0.001).ConclusionsWe report a significant increase in the number ofMI‐positive tests.MIis confirmed to be a rapidly emerging allergen, as also observed in otherEuropean countries.
Tissue antigens · 1995
Abstract: Rheumatoid arthritis (RA) occurs more frequently in HLA‐DR4+ individuals than in those who do not express this MHC class II molecule. Although the role of this genetic factor in the immunopathology of this autoimmune disease is unclear, the association of RA with HLA‐DR4 may indicate that DR4 molecules present autoantigen(s) to T cells. Here we report the analysis of naturally processed peptides, eluted from a mixture of HLA‐DR4Dw4 (DRB1*0401) and DR53 (DRB4* 0101) molecules isolated from an RA patient‐derived EBV‐transformed B cell line. Several (size variants of) self‐peptides originating from the autologous molecules HLA‐A2, HLA‐Cw9, HLA‐B62, HLA‐DR4Dw4 and HLA‐DR53, were identified. We also found a sequence that has no homology to any protein in the SwissProt protein sequence databank, and a peptide identical to an internal fragment of the autoantigen calreticulin. The association of the identified peptides with cells expressing HLA‐DR4Dw4/DR53 was confirmed by peptide binding analysis. In agreement with previously described peptide binding motifs for DR4Dw4, most peptides contained an aromatic residue (Phe, Tyr, Trp) at relative position i and a small hydroxyl‐containing residue (Ser, Thr) at i+5. Our findings indicate that in RA patient‐derived EBV‐transformed B cells DR4Dw4/ DR53 molecules present a peptide from the autoantigen calreticulin. Interestingly, autoantibodies against calreticulin have been found in various rheumatic diseases, including rheumatoid arthritis. Thus, the analysis of HLA class II‐bound peptides can lead to the identification of putative T helper epitopes, which might be involved in the immunopathology of autoimmune diseases.
Swiss medical weekly · 2003
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Contact dermatitis · 2014 · Journal Article
Hosteing S, Meyer N, Waton J, Barbaud A, et al.
Swiss medical weekly · 2003 · Case Reports
Ribi C, Vermeulen C, Hauser C
Southern medical journal · 2002 · Case Reports
Bachmeyer C, Vermeulen C, Habki R, Blay F, et al.
Presse medicale (Paris, France : 1983) · 2000 · Case Reports
Vermeulen C, Lemaire V, Lioté F
Tissue antigens · 1995 · Journal Article
Verreck FA, Elferink D, Vermeulen CJ, Amons R, et al.